Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine in previously treated patients with severe haemophilia B.

@article{Serban2012ClinicalES,
  title={Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine in previously treated patients with severe haemophilia B.},
  author={Maria-Corina Serban and Aleksander Bartłomiej Skotnicki and Milica Colovic and Cristian Marius Jinca and Anna Klukowska and Pawel Laguna and Debra M. Wolf},
  journal={Haemophilia : the official journal of the World Federation of Hemophilia},
  year={2012},
  volume={18 2},
  pages={175-81}
}
Plasma-derived factor IX (FIX) concentrate remains an important choice for replacement therapy in haemophilia B patients. Haemonine is a high purity double-virus inactivated human plasma-derived coagulation FIX concentrate (pdFIX). Aim was to evaluate the clinical efficacy, safety and pharmacokinetic properties of Haemonine in three prospective, open-label uncontrolled studies and a compassionate use program in previously treated patients with severe haemophilia B. Long-term efficacy and safety… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

References

Publications referenced by this paper.
Showing 1-10 of 13 references

Similar Papers

Loading similar papers…